COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Detailed Description
-----------------
To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/ critical proven SARS-CoV-2 infection in hospitalized patients and to evaluate the safety and tolerability of Fisetin in this patient population.

Official Title
-----------------
COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Fisetin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria - Patients must meet all of the following inclusion criteria to be enrolled in this study. Men or women 60 years of age or older OR Age 18 - 59 years WITH at least one of the following comorbidities: BMI greater than or equal to 35 Diabetes Asthma/ Chronic Obstructive Pulmonary Disease (COPD) Previous Myocardial Infarction Previous Stroke/ Cerebrovascular Accident (CVA) Hypertension/ Atherosclerosis/ Peripheral Vascular Disease Smoking and/or vaping Other conditions associated with senescent cell accumulation (i.e. previous chemotherapy or radiation) SpO2 greater than or equal to 85% (on room air or less than or equal to 2 L of supplemental oxygen) Willing and able to provide written informed consent or have a legally authorized representative (LAR) who will provide informed consent SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic (or other CLIA certified) laboratory within 10 days prior to randomization. Exclusion Criteria - Patients who meet any of the following exclusion criteria are not to be enrolled in this study. General Exclusion Criteria Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration Laboratory Exclusion Criteria Total bilirubin >3X upper limit of normal or as per clinical judgment. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) >4x the upper limits of normal or as per clinical judgment. Hemoglobin <7 g/dL; white blood cell count ≤ 2,000/mm3 (< or = 2.0 x 109/L) or > or = 20,000/mm3 (> or = 20 x 109/L); platelet count < or = 40,000/µL (< or = 40 x 109/L); absolute neutrophil count < or = 1 x 109/L; lymphocyte count <0.3 x 109/L at screening or as per clinical judgment. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine, immunological, or hepatic disorder. eGFR <25 ml/ min/ 1.73 m2 or as per clinical judgment. Plasma and/or serum glucose >300 or as per clinical judgment. Clinical History Exclusion Criteria Human immunodeficiency virus infection. Known active hepatitis B or C infection. Invasive fungal infection. Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites. New/active invasive cancer except non-melanoma skin cancers. Medication Exclusion Criteria (See Appendices 1-3 for additional information) Known hypersensitivity or allergy to Fisetin. Patients currently using medications which utilize CYP450 2C9 for metabolism. These medications include: Fosphenytoin, Phenytoin, Warfarin, Glimepiride, Diclofenac, Bosentan, and Glyburide. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible. Patients currently using medications which utilize CYP2C9, CYP2C19, CYP1A2, OATP1B1. These medications include: Olanzapine, Clozapine, Theophylline, Tizanidine, Warfarin, Rameltoen, Tacrine, Duloxetine, Mexiletine, Riluzole, and Atomoxetine. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible. Patients currently using medications which are strong inhibitors of CYP3A4. These medications include: Atazanavir, Ceritinib, Clarithromycin, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mefipristone, Nefazodone, Nelfinavir, Ombitasivir-paritaprevir-ritonivir, Ombitasivir-paritaprevir-ritonivir-plus dasabuvir, Posaconazole, Saquinavir, Telithromycin, Tucatinib, and Voriconazole. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible. Patients currently using antifungals. If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are subtherapeutic or therapeutic. Patients taking any of these medications may participate if the medications can be held immediately before the 1st IP administration until at least 10 hours after the last (2nd) IP administration and the patient is otherwise eligible: Cardiac: digoxin, flecainide, amiodarone Psychiatric: lithium, thioridazine Neurologic: carbamazepine, phenobarbital Antimicrobial/fungal: aminoglycosides (e.g. amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomysin, streptomycin, tobramycin), rifampin Anticoagulants/ Antiplatelets: warfarin Others: methotrexate, nitroglycerin, St. John's wort, tyrosine kinase inhibitors, tacrine, diclofenac Participation in other clinical trials involving treatment for SARS-CoV-2. (unless reviewed and approved by the Principal Investigator). Note that institutional standard of care treatment of SARS-CoV-2 including glucocorticoids, hydroxychloroquine, azithromycin, remdesivir, anti-spike antibodies, and/or convalescent plasma are not excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group<br>Subjects will receive treatment drug Fisetin | Drug: Fisetin<br>*  20 mg/kg/day oral, NG or D tube course for 2 consecutive days<br>* Other names: 3,3',4',7-tetrahydroxyflavone;|
| Placebo Comparator: Placebo Group<br>Subjects will receive placebo | Drug: Placebo<br>* Placebo looks exactly like the study drug, but it contains no active ingredient.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious Adverse Events | Number of participants to experience serious adverse events and hypersensitivity reactions. | 6 months | 
| Change in oxygenation status | change in oxygenation levels as measured by S/F ratio (SPO2/FiO2) | baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CoV Severity Category | Number of participants to progress to severe or critical classification CoV | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2